Literature DB >> 22351743

Mesothelin-targeted agents in clinical trials and in preclinical development.

Ronan J Kelly1, Elad Sharon, Ira Pastan, Raffit Hassan.   

Abstract

Mesothelin is a tumor differentiation antigen that is highly expressed in several malignant diseases in humans, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. The limited expression of mesothelin on normal human tissues and its high expression in many common cancers make it an attractive candidate for cancer therapy. Several agents, including an immunotoxin, monoclonal antibody, antibody drug conjugate, and tumor vaccine, are in various stages of development to treat patients with mesothelin-expressing tumors. This review highlights ongoing clinical trials, as well as other approaches to exploit mesothelin for cancer therapy, that are in preclinical development.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22351743      PMCID： PMC3297681          DOI： 10.1158/1535-7163.MCT-11-0454

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN： 1535-7163            Impact factor:   6.261


  46 in total

1.  Suppression of cell death by the secretory form of N-terminal ERC/mesothelin.

Authors:  Tegexibaiyin Wang; Kazunori Kajino; Masaaki Abe; Ke Tan; Masumi Maruo; Guodong Sun; Yoshiaki Hagiwara; Masahiro Maeda; Okio Hino
Journal:  Int J Mol Med       Date:  2010-08       Impact factor: 4.101

2.  Mesothelin is not required for normal mouse development or reproduction.

Authors:  T K Bera; I Pastan
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

3.  Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.

Authors:  Raffit Hassan; Megan R Lerner; Doris Benbrook; Stan A Lightfoot; Daniel J Brackett; Qing-Cheng Wang; Ira Pastan
Journal:  Clin Cancer Res       Date:  2002-11       Impact factor: 12.531

4.  Value of mesothelin immunostaining in the diagnosis of mesothelioma.

Authors:  Nelson G Ordóñez
Journal:  Mod Pathol       Date:  2003-03       Impact factor: 7.842

5.  Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.

Authors:  Qian Li; Claire F Verschraegen; John Mendoza; Raffit Hassan
Journal:  Anticancer Res       Date:  2004 May-Jun       Impact factor: 2.480

6.  Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1.

Authors:  Raffit Hassan; Juanita Williams-Gould; Thelma Watson; Lee Pai-Scherf; Ira Pastan
Journal:  Clin Cancer Res       Date:  2004-01-01       Impact factor: 12.531

7.  Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.

Authors:  Armin Rump; Yoshihiro Morikawa; Minoru Tanaka; Sawako Minami; Naohiko Umesaki; Masaki Takeuchi; Atsushi Miyajima
Journal:  J Biol Chem       Date:  2003-12-15       Impact factor: 5.157

8.  Application of mesothelin immunostaining in tumor diagnosis.

Authors:  Nelson G Ordóñez
Journal:  Am J Surg Pathol       Date:  2003-11       Impact factor: 6.394

9.  Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.

Authors:  Markku Miettinen; Maarit Sarlomo-Rikala
Journal:  Am J Surg Pathol       Date:  2003-02       Impact factor: 6.394

Review 10.  Mesothelin: a new target for immunotherapy.

Authors:  Raffit Hassan; Tapan Bera; Ira Pastan
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531
View more
  53 in total

1.  Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.

Authors:  Jonathan Villena-Vargas; Prasad S Adusumilli
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 2.  B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look.

Authors:  Jenessa B Smith; Caitlin Stashwick; Daniel J Powell
Journal:  Gynecol Oncol       Date:  2014-03-20       Impact factor: 5.482

3.  Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma.

Authors:  Prasad S Adusumilli
Journal:  Cancer       Date:  2014-07-02       Impact factor: 6.860

4.  Modulating Protein Stability to Switch Toxic Protein Function On and Off in Living Cells.

Authors:  Frederik Faden; Stefan Mielke; Nico Dissmeyer
Journal:  Plant Physiol       Date:  2019-01-24       Impact factor: 8.340

5.  Transpo-mAb display: Transposition-mediated B cell display and functional screening of full-length IgG antibody libraries.

Authors:  Lorenz Waldmeier; Ina Hellmann; Chantal K Gutknecht; Fabian I Wolter; Skylar C Cook; Sai T Reddy; Ulf Grawunder; Roger R Beerli
Journal:  MAbs       Date:  2016-03-17       Impact factor: 5.857

Review 6.  Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy.

Authors:  Marcela V Maus; Carl H June
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

Review 7.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Engineered Ovarian Cancer Cell Lines for Validation of CAR T Cell Function.

Authors:  Claire E Repellin; Priya Ganesan; Javier F Alcudia; Haritha K Duggireddy Lakshmireddy; Puja Patel; Lucia Beviglia; Harold S Javitz; Lidia Sambucetti; Parijat Bhatnagar
Journal:  Adv Biosyst       Date:  2019-11-29

9.  Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

Authors:  Gregory L Beatty; Andrew R Haas; Marcela V Maus; Drew A Torigian; Michael C Soulen; Gabriela Plesa; Anne Chew; Yangbing Zhao; Bruce L Levine; Steven M Albelda; Michael Kalos; Carl H June
Journal:  Cancer Immunol Res       Date:  2014-02       Impact factor: 11.151

10.  A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.

Authors:  Zhewei Tang; Mingqian Feng; Wei Gao; Yen Phung; Weizao Chen; Amit Chaudhary; Brad St Croix; Min Qian; Dimiter S Dimitrov; Mitchell Ho
Journal:  Mol Cancer Ther       Date:  2013-01-31       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.